Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxenda in Obese Patients With Knee Osteoarthritis (BIO-LOSEIT-II)
NCT02928614Phase 4Completed
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liraglutide in obesity and osteoarthritis (OA). Primary endpoint: collagen II degradation fragment α-C2M at 52 weeks. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
obesityosteoarthritis (OA)
Beyond the preview
Go deeper on NCT02928614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928614.